References
- Siegl PKS. Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J Hypertens 1993; 11: S19–S22
- Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin I1 receptor antagonists. A Rev Pharmacol Toxicol 1992; 32: 135–65
- Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5: 221s–2358
- Ganison JC, Peach MJ. Renin and angiotensin. The pharmacological basis of therapeutics 8th ed, AG Gilman, TW Rall, AS Nies, P. Taylor. McGraw-Hill, New York 1990; 749–63
- Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990; 15: S20–24
- O'Hollaren MT, Porter M. Angiotensin converting enzyme inhibitors and the allergist. Ann Allergy 1990; 64: 503–6
- Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens 1993; 11: S49–S52
- Cockcroft JR, Sciberras DG, Goldberg MR, Ritter Jm. Comparison of angiotensin converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993; 22: 579–84
- Lacourciere Y, Brunner H, Irwin R. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 387
- Goldberg AI, Dunlay MC, Sweet CS. The safety and tolerability of losartan potassium, an angiotensin II receptor antagonist in comparison to hydrochlorothiazide, atenolol, felodipine ER and ACE-Inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–5
- Nelson EB, Merrill DM, Sweet CS, Bradstreet T, Parebianco D, Byyny R. Efficacy and safety of oral MK-954 (DuP753), an angiotensin receptor antagonist in essential hypertension. J Hypertens 1991; 9: S468–S469
- Gradman AH, Arcuri KE, Goldberg AI. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared to enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1339
- Christen Y, Waeber B, Nussberger J. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333
- Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PBMWM, Brunner HR. Dose-response relationship following oral administration of DuP 753 to normal humans. Am J Hypertens 1991; 4: 350s–53s
- Meredith PA. Trough/peak ratios for antihypertensive agents. Drugs 1994; 48: 661–6
- Schnaper HW, Stein G, Schoenberger JA. Enalapril, hydrochlorothiazide and plasma renin activity in elderly patients with essential hypertension. Curr Opin Cardiol 1987; 2: S39–S50
- Forette F, Handfield-Jones R, Henry-Amar M. Rationale for ACE inhibitors in the elderly, trial of arterial hypertension with enalapril. Gerontology 1987; 33: 9–16